EUCTR2019-004536-37-DE进行中（未招募）1 期
Treatment of MDS/AML patients with an impending hematological relapse with azacitidine alone or in combination with pevonedistat - a randomized phase 2 trial - SHAPE
eipzig University0 个研究点目标入组 14 人开始时间: 2020年6月16日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- AML or MDS
- •- continuing first CR after conventional intensive chemotherapy OR continuing CR after alloSCT
- •- MRD positivity (assessed by local lab) as defined by:
- •o NPM1mut status >1% in peripheral blood or bone marrow in NPM1 mutated patients at diagnosis or
- •o Patients after allogeneic transplantation, who were NPM1 unmutated at diagnosis and have a blood or marrow CD34/CD117 chimerism <80%
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 76
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 26
排除标准
- •Compliance with major study procedures
- •- Patient does not accept bone marrow sampling during screening, primary end point visit and after the treatment.
- •- Patient does not accept several blood sampling during screening, treatment (up to bi-daily) and after the treatment.
- •- Inadequate organ function as defined in the list below:
- •o Absolute neutrophil count (ANC) < 1.5 Gpt/L
- •o Platelets < 100 Gpt/L
- •o Albumin < 2.7 g/dL
- •o Creatinine clearance < 30 mL/min (Cockcroft und Gault formula)
- •o Total bilirubin > 1.5xupper limit of normal (ULN)19 except in patients with Gilbert’s syndrome. Patients with Gilbert’s syndrome may be enrolled if direct bilirubin > 1.5x ULN of the direct bilirubin.
- •o Both Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 3.0 ULN
- •- ECOG performance status of =2
- •Concomitant Diseases
- •- Liver cirrhosis or severe pre-existing hepatic impairment
- •- Known severe cardiopulmonary disease (e.g. unstable angina, congestive heart failure NYHA III or IV, myocardial infarction within 6 months prior to screening, symptomatic cardiomyopathy, clinically significant arrhythmia20, clinically significant pulmonary hypertension requiring pharmacologic therapy)
- •- Uncontrolled high blood pressure (i.e. systolic blood pressure > 180 mm Hg, diastolic blood pressure > 95 mm Hg)
- •- Known prolonged rate corrected QT interval = 500 msec, calculated according to institutional guidelines
- •- Known left ventricular ejection fraction < 50% as assessed by echocardiogram or radionuclide angiography
- •- Known moderate to severe symptomatic chronic obstructive pulmonary disease, interstitial lung disease, or pulmonary fibrosis
- •- Active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, or septicemia
- •- Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •- Known Human Immunodeficiency Virus (HIV 1/2 antibodies)
- •- Known active Hepatitis B (i.e. HBsAg reactive) or Hepatitis C (i.e., HCV RNA [qualitative] is detected). NOTE: Patients who have isolated positive hepatitis B core antibody (i.e. in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load. Patients who have positive hepatitis C antibody may be included if they have an undetectable hepatitis C viral load.
- •- Major surgery within 14 days of randomization or a scheduled surgery during study period
- •- Known central nervous system (CNS) involvement
- •- Diagnosis or treatment for another malignancy within 2 years before randomization. (NOTE: Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection. Prior diagnosis of myelodysplasia, myeloproliferative neoplasm, or aplastic anemia and treatment for that diagnosis does not lead to exclusion)
- •- Any evidence of residual disease of another malignancy
- •- Patients with uncontrolled coagulopathy or bleeding disorder
- •- History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the in the best interest of the subject to participate, in the opinion of the treating investigator
- •Prior unfavourable effect of HMA monotherapy
- •- Prior HMA failure
- •- Prior HMA treatment without subsequent allogeneic transplantation
- •Interfering Treatments
研究者
相似试验
进行中（未招募）
1 期
Treatment of an imminent recurrence of the disease in patients with a Myelodysplastic syndrome or acute myeloid leukemia with azacitidine (Vidaza®)EUCTR2010-022388-37-DETechnische Universität Dresden93
已完成
2 期
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and PevonedistatAcute Myeloid Leukemia in RemissionMyelodysplastic SyndromesMinimal Residual DiseaseNCT04712942University of Leipzig14
进行中（未招募）
不适用
Treatment of MDS patients with single agent temsirolimus – a pilot studyMyelodysplastic Syndromes (MDS)(20 IPSS LOW+INT-1 and 20 IPSS INT-2+HIGH or proliferating CMML)MedDRA version: 14.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014768-21-DEDresden Technical University
进行中（未招募）
不适用
Traitement des syndromes myélodysplasiques par l'association aracytine et bortezomibMyelodysplastic syndrome (MDS) is a clonal disease of the bone marrow stem cells. The disease is frequently associated with cytopenia and/or blastosis. An evolution to an acute leukemia is not unfrequent (~ 30%). Treatments are very disapointing especially for high risk MDS. The prognosis mainly depends on blastosis, cytopenia and cytogenetic abnormalities but the disease is typically uncurable (except BMT).EUCTR2005-005794-29-BEGroupe français des Myélodysplasies39
进行中（未招募）
不适用
TREATMENT OF MINIMAL RESIDUAL DISEASE (MRD) IN ACUTE LEUKEMIA AFTER AN ALLOGENEIC STEM CELL TRANSPLANT - NDPatients with acute leukemia and positive MRD post allogeneic hemopoietic stem cell transplant (HSCT)MedDRA version: 9.1Level: LLTClassification code 10000830Term: Acute leukaemiaEUCTR2007-005864-28-ITFONDAZIONE RICERCA TRAPIANTO DI MIDOLLO OSSEO